Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Makoto Nishio

The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models

Nature Communications

English

Prediction of ALK Mutations Mediating ALK-TKIs Resistance and Drug Re-Purposing to Overcome the Resistance

English

First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors

Molecular Cancer Therapeutics

Cancer Research

Oncology

2019

English

Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib

English

Exploration of Resistance Mechanisms for EGFR-TKIs Based on Plasma Analysis by Digital PCR and Next-Generation Sequencing

English

Real-World Effectiveness and Safety of Nivolumab in Patients With Non-Small Cell Lung Cancer: A Multicenter Retrospective Observational Study in Japan

English

Corrigendum to “Analysis of Central Nervous System Efficacy in the J-Alex Study of Alectinib Versus Crizotinib in ALK-positive Non-Small-Cell Lung Cancer” [Lung Cancer 121 (July) (2018) Pages 37–40]

English

A Randomized, Double-Blind, Phase II Study of Ramucirumab Plus Docetaxel vs Placebo Plus Docetaxel in Japanese Patients With Stage IV Non-Small Cell Lung Cancer After Disease Progression on Platinum-Based Therapy

English

Podoplanin Enhances Lung Cancer Cell Growth in Vivo by Inducing Platelet Aggregation

Scientific Reports

Multidisciplinary

2017

English

Three‐year Follow‐up Results From Phase II Studies of Nivolumab in Japanese Patients With Previously Treated Advanced Non‐small Cell Lung Cancer: Pooled Analysis of ONO‐4538‐05 and ONO‐4538‐06 Studies

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Makoto Nishio

The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models

Prediction of ALK Mutations Mediating ALK-TKIs Resistance and Drug Re-Purposing to Overcome the Resistance

First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors

Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib

Exploration of Resistance Mechanisms for EGFR-TKIs Based on Plasma Analysis by Digital PCR and Next-Generation Sequencing

Real-World Effectiveness and Safety of Nivolumab in Patients With Non-Small Cell Lung Cancer: A Multicenter Retrospective Observational Study in Japan

Corrigendum to “Analysis of Central Nervous System Efficacy in the J-Alex Study of Alectinib Versus Crizotinib in ALK-positive Non-Small-Cell Lung Cancer” [Lung Cancer 121 (July) (2018) Pages 37–40]

A Randomized, Double-Blind, Phase II Study of Ramucirumab Plus Docetaxel vs Placebo Plus Docetaxel in Japanese Patients With Stage IV Non-Small Cell Lung Cancer After Disease Progression on Platinum-Based Therapy

Podoplanin Enhances Lung Cancer Cell Growth in Vivo by Inducing Platelet Aggregation

Three‐year Follow‐up Results From Phase II Studies of Nivolumab in Japanese Patients With Previously Treated Advanced Non‐small Cell Lung Cancer: Pooled Analysis of ONO‐4538‐05 and ONO‐4538‐06 Studies